SCHEMBL31433203

SCHEMBL31433203

CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](C)N)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 8/20 0.47
LTA4H P09960 1/20 0.44
PSEN1 P49768 4/20 0.42
PSEN2 P49810 4/20 0.42
APH1B Q8WW43 4/20 0.42
NCSTN Q92542 4/20 0.42
APH1A Q96BI3 4/20 0.42
PSENEN Q9NZ42 4/20 0.42
MMP3 P08254 3/20 0.42
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
REN P00797 2/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 1/20 0.40
PSMB11 A5LHX3 1/20 0.40
PSMA7 O14818 1/20 0.40
PSMB1 P20618 1/20 0.40
PSMA1 P25786 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31433190 0.89 MMP3 (0.47) CPB2PSEN1PSEN2APH1BNCSTN
SCHEMBL31433304 0.86 FNTA (0.44) CPB2LTA4HPSEN1PSEN2APH1B
SCHEMBL31433325 0.85 FNTA (0.46) CPB2LTA4HPSEN1PSEN2APH1B
SCHEMBL7751628 0.85 CPB2 (0.51) CPB2LTA4H
SCHEMBL1711472 0.83 ALDH1A1 (0.51) LTA4HMEN1ALDH1A1LMNAKMT2A
SCHEMBL29629477 0.83 ALDH1A1 (0.51) LTA4HMEN1ALDH1A1LMNAKMT2A
SCHEMBL29531361 0.83 ALDH1A1 (0.51) LTA4HMEN1ALDH1A1LMNAKMT2A
SCHEMBL1711477 0.83 ALDH1A1 (0.51) LTA4HMEN1ALDH1A1LMNAKMT2A
SCHEMBL15443060 0.83 ALDH1A1 (0.55) LTA4HMEN1ALDH1A1LMNAKMT2A
SCHEMBL29538996 0.83 ALDH1A1 (0.55) LTA4HMEN1ALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074942-A1 COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E CALICO LIFE SCIENCES LLC (US) 2025-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074942-A1 COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E MICA, CD74, HLA-DRB1 CPB2 948/4885LTA4H 1057/4885PSEN1 4057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.